CD44 and breast carcinoma: So, in this study the status of CD24-CD44 breast cancer stem cell markers was studied in MDA-MB231 triple negative breast cancers (Figure 1) and due to absolute dominance of CD44+CD24low/- phenotype (96.3%±1.7), the cell line was used without further cell sorting.